Taylor v. Reckitt Benckiser Pharmaceuticals, Inc.

CourtDistrict Court, E.D. New York
DecidedJanuary 31, 2025
Docket1:23-cv-08783
StatusUnknown

This text of Taylor v. Reckitt Benckiser Pharmaceuticals, Inc. (Taylor v. Reckitt Benckiser Pharmaceuticals, Inc.) is published on Counsel Stack Legal Research, covering District Court, E.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Taylor v. Reckitt Benckiser Pharmaceuticals, Inc., (E.D.N.Y. 2025).

Opinion

UNITED STATES DISTRICT COURT EASTERN DISTRICT OF NEW YORK -------------------------------------------------------x TIFFANY TAYLOR, on behalf of herself and all others similarly situated,

Plaintiff, MEMORANDUM & ORDER 23-CV-8783 (PKC) (TAM) - against -

RECKITT BENCKISER PHARMACEUTICALS INC.,

Defendant. -------------------------------------------------------x PAMELA K. CHEN, United States District Judge: Plaintiff Tiffany Taylor (“Plaintiff”) commenced this putative class action against RB Health (US) LLC (incorrectly sued as “Reckitt Benckiser Pharmaceuticals Inc.,” hereinafter “Defendant” or “Reckitt”) on November 29, 2023. Plaintiff alleges that Defendant engaged in deceptive acts and false advertising by marketing certain Mucinex products as though they contain honey, even though they do not, in violation of New York General Business Law (“NYGBL”) Sections 349 and 350. (See Compl., Dkt. 1.) Presently before the Court is Defendant’s motion to dismiss pursuant to Federal Rule of Civil Procedure (“Rule”) 12(b)(1) and Rule 12(b)(6). For the reasons set forth below, Defendant’s motion to dismiss is granted, and Plaintiff’s Complaint is dismissed in its entirety. BACKGROUND I. Factual Allegations! A. The Mucinex Products The Mucinex products at issue are four types of non-prescription liquid cold and cough medicine (the “Mucinex Honey Products”)—two for adults and two for children.” (Compl., Dkt. 1, {| 1. 3.) Defendant Reckitt “is responsible for the marketing, advertising, trade dress, labeling, and packaging of the Mucinex Honey Products.” (/d. J 10.) In her Complaint, Plaintiff includes the following images of the Adult Mucinex Products:

= =4 = SUEY Ze ‘Mucinex iMucinex: Sura ea > CHEST CONGESTION DM MAX ns ce MAI a (ey ou %, en a PAUSE Were acy Auteurs) ris Atay aura oct □□□ rt) peers i Bley GELB) ey osaes

' For purposes of Defendant’s Rule 12(b)(6) motion, the Court “accept[s] all well-pleaded allegations in the complaint as true, drawing all reasonable inferences in the plaintiff's favor.” Int'l Code Council, Inc. v. UpCodes Inc., 43 F.4th 46, 53 (2d Cir. 2022) (quoting Operating Loc. 649 Annuity Tr. Fund v. Smith Barney Fund Mgmt. LLC, 595 F.3d 86, 91 (2d Cir. 2010)); Hamilton v. Westchester County, 3 F.4th 86, 90-91 (2d Cir. 2021) (same). > The products that make up the Mucinex Honey Products are two adult products: Mucinex Fast-Max Chest Congestion Honey & Berry Flavor and Mucinex Fast-Max DM Max Honey & Berry Flavor (the “Adult Mucinex Products”), and two children’s products: Mucinex’s Children’s FreeFrom Multi-Symptom Cold & Stuffy Nose Honey & Berry Natural Flavor and Mucinex’s Children’s FreeFrom Cough & Mucus Honey & Berry Natural Flavor (the “Children’s Mucinex Products”). (Compl., Dkt. 1, 7 3.)

Ud. Jj 22, 24.) The front packaging of the Adult Mucinex Products includes the phrase “Honey & Berry Flavor,” with the text “Honey” bolded and larger than the text “& Berry Flavor.” (d.) The front packaging also shows “a honey dripper dripping honey over a honeycomb” and a “swirling liquid honey background.” (d. § 22; see also id. § 24.) On the back of the Adult Mucinex Products is a peel-back label with the text “peel corner to read complete drug facts and information.” (Ud. 428.) Underneath the peel-back label are drug facts, directions, and other information, including a list of inactive ingredients. Ud. 429.) The list of inactive ingredients includes “flavors,” but does not include honey.? (Id. J] 29-30.) Additionally, Plaintiff provides the following images of the Children’s Mucinex Products: > owe DAYTIME Mucinex Mucinex | es eos

Le mE mT 11 i il ie □□□ aT a hu, a Nala Co aN = [toca ctntms-acoovwen] [encima & wnt ONE i % fi HONEY ines, FLORIO ieiRs, oT ORLDTB

3 Plaintiff also provides an image of advertising for the Adult Mucinex Products from the Mucinex website—which includes images of honey and honeybees with the text “TAKE THE STING OUT OF YOUR COLD”—but does not claim to have seen or relied on this advertisement prior to purchasing the Adult Mucinex Products. (See Compl., Dkt. 1, J 26.)

(Id. ¶ 32.) The Children’s Mucinex Products depict “Mr. Mucus,” a cartoon character “dressed in a yellow and black honeybee colored shirt, holding a honey dripper dripping honey, and surrounded by honeybees . . . .” (Id. ¶ 31.) The phrase “Honey & Berry Natural Flavor” is on the front of the package, with the word “honey” in a “prominent” and “bold” font above the rest of the phrase. (Id. ¶¶ 31–32.) Plaintiff also provides images of the back panel of one of the Children’s

Mucinex Products, which again has the text “Honey & Berry Natural Flavor,” but does not include honey among the inactive ingredients. (Id. ¶¶ 33–34.) B. Plaintiff’s Purchase of Mucinex Honey Products In or around May 2023, Plaintiff purchased Mucinex Fast-Max Chest Congestion Honey & Berry Flavor, one of the Adult Mucinex Products, at a supermarket in Queens, New York. (Id. ¶ 36.) Prior to her purchase, Plaintiff saw “the representations on the front [of the packaging] with honey-based imagery of a honey dripper dripping honey over a honeycomb and swirling liquid honey background and the bold and honey-colored word ‘HONEY.’” (Id. ¶ 37.) Plaintiff states that she believed the product contained honey, and that if she had known it did not contain honey, “she would not have purchased Defendant’s products or, at the very least, would not have paid a

price premium for Defendant’s Mucinex Honey Products.” (Id. ¶¶ 38–39.) II. Procedural History Plaintiff filed the Complaint on November 29, 2023, alleging two causes of action: (1) Violation of NYGBL Section 349 for deceptive acts and practices, (id. ¶¶ 48–59); N.Y. Gen. Bus. Law § 349, and (2) Violation of NYGBL Section 350 for false advertising, (id. ¶¶ 60–66); N.Y. Gen. Bus. Law § 350. On December 21, 2023, the Court directed Plaintiff to file a letter clarifying her citizenship for the purposes of diversity jurisdiction. (12/21/2023 Dkt. Order.) Plaintiff filed a letter in response on December 27, 2023, confirming that she is a New York domiciliary. (Dkt. 12.) On March 7, 2024, Defendant requested a pre-motion conference (“PMC”) for its anticipated motion to dismiss. (Dkt. 16.) Plaintiff filed a response to Defendant’s PMC request on March 22, 2024. (Dkt. 19.) The Court denied Defendant’s PMC request as unnecessary and set a briefing schedule for the motion to dismiss. (4/4/2024 Dkt. Order.) Defendant’s motion to dismiss was fully briefed as of June 19, 2024. (See Dkts. 23–26.) III. Jurisdiction, Venue, and the Putative Class

Plaintiff contends that the Court has subject matter jurisdiction pursuant to the Class Action Fairness Act of 2005 (“CAFA”), 28 U.S.C. § 1332(d), because the amount in controversy is over $5,000,000 and she and Defendant are citizens of different states. (Compl., Dkt. 1, ¶ 11); 28 U.S.C. § 1332(d)(2)(A). Plaintiff asserts that the Court also has jurisdiction under 28 U.S.C. § 1332(a), (Compl., Dkt. 1, ¶ 12), and that venue in this District is proper pursuant to 28 U.S.C.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Spagnola v. Chubb Corp.
574 F.3d 64 (Second Circuit, 2009)
Cohen v. JP Morgan Chase & Co.
498 F.3d 111 (Second Circuit, 2007)
McCarthy v. Dun & Bradstreet Corp.
482 F.3d 184 (Second Circuit, 2007)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
DiFolco v. MSNBC Cable L.L.C.
622 F.3d 104 (Second Circuit, 2010)
Natalia Makarova v. United States
201 F.3d 110 (Second Circuit, 2000)
Fink v. Time Warner Cable
714 F.3d 739 (Second Circuit, 2013)
Goshen v. Mutual Life Insurance
774 N.E.2d 1190 (New York Court of Appeals, 2002)
Oswego Laborers' Local 214 Pension Fund v. Marine Midland Bank, N. A.
647 N.E.2d 741 (New York Court of Appeals, 1995)
Koch v. ACKER, MERRALL & CONDIT COMPANY
967 N.E.2d 675 (New York Court of Appeals, 2012)
Hogan v. Fischer
738 F.3d 509 (Second Circuit, 2013)
Orlander v. Staples, Inc.
802 F.3d 289 (Second Circuit, 2015)
Hamilton v. Westchester Cnty.
3 F.4th 86 (Second Circuit, 2021)
Chambers v. Time Warner, Inc.
282 F.3d 147 (Second Circuit, 2002)

Cite This Page — Counsel Stack

Bluebook (online)
Taylor v. Reckitt Benckiser Pharmaceuticals, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/taylor-v-reckitt-benckiser-pharmaceuticals-inc-nyed-2025.